Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556241 | 0.90 | DPYD (0.44) | DPYDGAAATAD2 | |
| SCHEMBL5800398 | 0.81 | — | — | |
| SCHEMBL161148 | 0.79 | ATAD2 (0.54) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL6555485 | 0.77 | DPYD (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL2584919 | 0.77 | LMNA (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL2037916 | 0.77 | DPYD (0.46) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL4625879 | 0.77 | ALDH1A1 (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL31236144 | 0.76 | DPYD (0.45) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL4346481 | 0.76 | DPYD (0.45) | DPYDGAAATAD2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL22659843 | 0.76 | DPYD (0.45) | DPYDGAAATAD2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | claimed |
| US-20260038646-A1 | MACHINE-LEARNED PHARMACOLOGY OPTIMIZATION | CREYON BIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260024621-A1 | OLIGONUCLEOTIDE-BASED MACHINE LEARNING | CREYON BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12400739-B2 | Oligonucleotide-based machine learning | CREYON BIO, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12374431-B2 | Machine-learned pharmacology optimization | CREYON BIO, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250122577-A1 | A METHOD FOR DETECTION OF POINT MUTATIONS IN TARGET NUCLEIC ACID USING LOOP-MEDIATED ISOTHERMAL AMPLIFICATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-04-17 | — | — | US | disclosed |
| US-20240404636-A1 | OLIGONUCLEOTIDE-BASED MACHINE LEARNING | CREYON BIO, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4746352-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1988-05-24 | — | — | US | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| US-4719214-A | HERPES VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0222192-A2 | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil | Sloan-Kettering Institute For Cancer Research (US) | 1987-05-20 | — | — | EP | disclosed |
| EP-0195346-A2 | 3-Aryl uraciles and their use as herbicides | CIBA-GEIGY AG (CH) | 1986-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260024621-A1 | OLIGONUCLEOTIDE-BASED MACHINE LEARNING | POLN, TOP1, NCL | DPYD 536/4885GAA 1486/4885ATAD2 750/4885 |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | DPYD 519/4885GAA 3190/4885ATAD2 2080/4885 |
| US-20260038646-A1 | MACHINE-LEARNED PHARMACOLOGY OPTIMIZATION | MAX, JUND, KCNJ8 | DPYD 2842/4885GAA 1545/4885ATAD2 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.